Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic

References

• Index Mundi. Czech Republic demographics profile 2012. http://www.indexmundi.com/czech_republic/demographics_profile.html. Accessed February 13, 2013
   Google Scholar
• Bryndová L, Pavloková K, Roubal T, et al. Czech Republic: health system review. Health Systems in Transition 2009;11:1-122. www.euro.who.int_data/assets/pdf_file/0003/75144/E86823.pdf. Accessed November 21, 2012
   Google Scholar
• Kinkorová J, Topolčan O. Overview of healthcare system in the Czech Republic. EPMA J 2012;3:1-8
   Google Scholar
• Hosák L, Bahbouh R. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. Eur Psychiatry 2002;17:213-21
   PubMed Web of Science ®Google Scholar
• Skoupá J, Cerna V, Dolezal T. Cost-effectiveness-analysis of risperidone long-acting injection in schizophrenia: 12 month data from Czech Republic. Presented at the 11th Annual ISPOR European Congress, Athens, Greece, November 9-11, 2008
   Google Scholar
• Skoupá J. Cost-effectiveness analysis of risperidone ling-acting injection in schizophrenia: 24-month data from Czech Republic. Value Health 2010;13:A451-2
   Google Scholar
• Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-16
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Cesková E. [Compliance in psychiatry]. Cas Lek Cesk 2009;148:489-92
   Google Scholar
• Svestka J, Bitter I. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders. Neuro Endocrinol Lett 2007;28(1 Suppl):95-116
   Google Scholar
• Mohr P. Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuro Endocrinol Lett 2007;28(1 Suppl):117-33
   Google Scholar
• Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-7
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xeplion® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf. Accessed November 21, 2012
   Google Scholar
• European Medicines Agency. Zypadhera® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf. Accessed November 21, 2012
   Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schiz Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough D, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-31
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer J-P, Lull JM, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychiatry 2010;30:235-44
   Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010;25:685-97
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane L, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011:1-12 . [Epub ahead of print]
   Web of Science ®Google Scholar
• European Medicines Agency. Risperdal Consta® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_Consta_30/WC500008170.pdf. Accessed November 21, 2012
   Google Scholar
• Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 2005;19:15-21
   PubMed Web of Science ®Google Scholar
• Lee M, Ko Y, Lee S, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407
   PubMed Web of Science ®Google Scholar
• Lindenmayer J-P, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-44
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodrigues-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Möller H-J, Llorca P-M, Sacchettii E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30
   PubMed Web of Science ®Google Scholar
• Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-9
   PubMed Web of Science ®Google Scholar
• Kane J, Detke H, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Peng X, Montgomery W, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. Eur Psychiatry 2011;26:313-9
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Committee for Proprietary Medicinal Products. Summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Leponex and associated names. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Leponex_30/WC500010966.pdf. Accessed November 21, 2012
   Google Scholar
• Ascher-Svanum H, Faries D, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
   PubMed Web of Science ®Google Scholar
• Nicholl D, Akhras K, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943-55
   PubMed Web of Science ®Google Scholar
• Olivares J, Peuskens J, Pecanek J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry -Mental Health Policy and Economics, Venice, Italy, 25-27 March 2011
   Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham, 1998
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004;71:155-75
   PubMed Web of Science ®Google Scholar
• Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56
   Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8
   PubMed Web of Science ®Google Scholar
• State Institute for Drug Control (SÚKL). Reimbursement list (11/2012). www.sukl.cz. Accessed November 21, 2012
   Google Scholar
• Psychiatric care. Series: Health Statistics 2012. Prague: Institute of Health Information and Statistics of the Czech Republic, www.uzis.cz. Accessed February 13, 2013
   Google Scholar
• Hospitalization by classification DRG. Series: Health Statistics 2012. Prague: Institute of Health Information and Statistics of the Czech Republic, www.uzis.cz. Accessed February 13, 2013
   Google Scholar
• Act 411/2011: The list of reimbursement for medical procedures 2012. Prague: Institute of Health Information and Statistics of the Czech Republic, www.uzis.cz. Accessed February 13, 2013
   Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26:733-44
   PubMed Web of Science ®Google Scholar
• Zvolský P, Hulínský J. [Clozapine–an atypical antipsychotic agents, its advantages and risks]. Cesk Psychiatr 1994;90:328-40
   Google Scholar
• Sidlova M, Prasko J, Jelenova D, et al. The quality of life of patients suffering from schizophrenia–a comparison with healthy controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:173-80
   Web of Science ®Google Scholar
• Hosák L, Bahbouh R. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic. Eur Psychiatry 2002;17:213-21
   PubMed Web of Science ®Google Scholar
• All Wales Medicines Strategy Group. Final appraisal report: Olanzapine depot (ZypAdhera®). Penarth, Wales: Lilly UK, 2010. Advice No: 1510. http://www.wales.nhs.uk/sites3/Documents/371/olanzapine%20depot%20(ZypAdhera)%20schizophrenia.pdf. Accessed April 4, 2013
   Google Scholar
• Farahati F, Boucher M, Moulton K, et al. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Heath, 2007
   Google Scholar
• Papageorgiou G, Cañas F, Zink M, et al. Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe. Eur Psychiatry 2011;26(1 Suppl):17-28
   Google Scholar
• Vevera J, Hubbard A, Veselý A, et al. Violent behaviour in schizophrenia. Retrospective study of four independent samples from Prague, 1949 to 2000. Br J Psychiatry 2005;187:426-30
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res 2012;12:259-69
   PubMed Web of Science ®Google Scholar